Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director | June 10, 2026 | June 12, 2026 |
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | Director | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2036-06-10 | Direct | 50,500 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 50,500 · Balance 50,500 F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 75,085 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 75,085 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date.
LISATA THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,659 |
Reported balance
After 2026-01-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 30,456 · Balance 95,659 F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2: Includes 30,456 unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027.
F2: Includes 30,456 unvested restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CAMBREX CORP
Report date December 04, 2019 · Filed December 05, 2019
Section 16 reporting ended · disclosed 2019-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-12-04 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-12-04 · Exercise / conversion · Acquired 360 · Balance 4,269 Row 2 · 2019-12-04 · Exercise / conversion · Acquired 1,980 · Balance 6,249 Row 3 · 2019-12-04 · Exercise / conversion · Acquired 2,766 · Balance 9,015 Row 4 · 2019-12-04 · Sale · Disposed 9,015 · Balance 0 F1: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.23 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-04 · Exercise / conversion · Acquired 360 · Balance 0 F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.70 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-04 · Exercise / conversion · Acquired 1,980 · Balance 0 F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.06 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-12-04 · Exercise / conversion · Acquired 2,766 · Balance 0 F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement.
F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 11:42 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 50,500 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001214659-26-007395 · marketforms-73381.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,500 Underlying: Common Stock · 50,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:03 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 30,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001373585-26-000003 · wk-form4_1768338222.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,659 F1 · shares: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2 · balance_after: Includes 30,456 unvested restricted stock units. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 14:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 42,000 | $3.41 Strike: $3.41 | $143,220.00 |
DisclosureSEC source: 0001214659-25-009128 · marketforms-69477.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 11, 2026, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:06 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 15,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001373585-25-000002 · wk-form4_1736802363.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,203 F1 · shares: Represents 15,789 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2026. F2 · balance_after: Includes 15,789 unvested restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 13:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 38,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001214659-24-011219 · marketforms-66323.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 20, 2025, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:04 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 19,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001373585-24-000002 · wk-form4_1705007053.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,414 F1 · shares: Represents 19,480 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2025. F2 · balance_after: Includes 19,480 unvested restricted stock units. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 13:41 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 25,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001214659-23-008799 · marketforms-61958.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 21, 2024, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:13 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001373585-23-000004 · wf-form4_167347161752987.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,934 F1 · shares: Represents 20,000 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2024. F2 · balance_after: Includes 24,362 unvested restricted stock units. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 17:02 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 25,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001214659-22-008292 · marketforms-56514.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 65,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001373585-22-000002 · wf-form4_164202157345903.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,040 F1 · shares: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2 · balance_after: Includes 103,165 unvested restricted stock units. Read SEC document |
| June 15, 2021 Filed Jun 21, 2021 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 20,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001214659-21-006757 · marketforms-53152.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:14 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 37,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001373585-21-000003 · wf-form4_161049328096383.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,610 F1 · shares: Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022. F2 · balance_after: Includes 56,027 unvested restricted stock units. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:12 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 14,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-20-005776 · marketforms-49051.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 16, 2021, subject to Mr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| January 13, 2020 Filed Jan 14, 2020 21:13 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 18,292 | $3.28 | $59,997.76 |
DisclosureSEC source: 0001373585-20-000002 · wf-form4_157903639231877.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,875 F1 · shares: Represents 18,292 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 13, 2021. F2 · balance_after: Includes 18,292 unvested restricted stock units. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:32 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 2,766 | $0.00 Strike: $40.06 | $0.00 |
DisclosureSEC source: 0001209191-19-059238 · doc4.xml · derivative · entry 7 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F2 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:32 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 1,980 | $0.00 Strike: $53.70 | $0.00 |
DisclosureSEC source: 0001209191-19-059238 · doc4.xml · derivative · entry 6 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,980 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F2 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:32 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 360 | $0.00 Strike: $44.23 | $0.00 |
DisclosureSEC source: 0001209191-19-059238 · doc4.xml · derivative · entry 5 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F2 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:32 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 9,015 | $60.00 | $540,900.00 |
DisclosureSEC source: 0001209191-19-059238 · doc4.xml · nonDerivative · entry 4 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:32 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 2,766 | $40.06 | $110,805.96 |
DisclosureSEC source: 0001209191-19-059238 · doc4.xml · nonDerivative · entry 3 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:32 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 1,980 | $53.70 | $106,326.00 |
DisclosureSEC source: 0001209191-19-059238 · doc4.xml · nonDerivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:32 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 360 | $44.23 | $15,921.00 |
DisclosureSEC source: 0001209191-19-059238 · doc4.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:42 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 13,350 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001214659-19-004250 · marketforms-45220.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,350 Underlying: Common Stock · 13,350 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 13, 2020, subject to Mr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| April 24, 2019 Filed Apr 25, 2019 20:33 UTC | CAMBREX CORP CBM · Entity 153359 | GrantStock Option (right to buy) · Derivative | 2,766 | $0.00 Strike: $40.06 | $0.00 |
DisclosureSEC source: 0001209191-19-026059 · doc4.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,766 Underlying: Common Stock · 2,766 shares Expires 2026-04-23 Read SEC document |
| April 24, 2019 Filed Apr 25, 2019 20:33 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 2,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026059 · doc4.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,909 Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:02 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 12,121 | $4.95 | $59,998.95 |
DisclosureSEC source: 0001373585-19-000013 · wf-form4_154767252002651.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,583 F1 · shares: Represents 12,121 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 14, 2020. F2 · balance_after: Includes 12,121 unvested restricted stock units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:10 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 8,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001373585-19-000010 · wf-form4_154714018596063.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,462 F1 · shares: Represents 8,747 shares underlying restricted stock granted under the 2018 Equity Incentive Compensation Plan which were awarded on January 8, 2018 and which vested on January 8, 2019. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:09 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 26,700 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033740 · form4.xml · derivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 25% of the underlying shares vest on the first anniversary of the grant date, 25% of the underlying shares vest on the second anniversary of the grant date and the remaining 50% of the underlying shares vest on the third anniversary of the grant date, subject in each case to Mr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 20:43 UTC | CAMBREX CORP CBM · Entity 153359 | GrantStock Option (right to buy) · Derivative | 1,980 | $0.00 Strike: $53.70 | $0.00 |
DisclosureSEC source: 0001209191-18-026941 · doc4.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,980 Underlying: Common Stock · 1,980 shares Expires 2025-04-25 Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 20:43 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 1,397 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-026941 · doc4.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,662 Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units · Derivative | 8,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001697 · tv483049_4.xml · derivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,747 Underlying: Common Stock · 8,747 shares Expires 2028-01-08 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the date that is one year from the date of grant. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 16:25 UTC | CAMBREX CORP CBM · Entity 153359 | GrantStock Option (right to buy) · Derivative | 360 | $0.00 Strike: $44.23 | $0.00 |
DisclosureSEC source: 0001437749-17-018158 · rdgdoc.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360 Underlying: Common Stock · 360 shares Expires 2024-10-31 Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 16:25 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 265 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-018158 · rdgdoc.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265 Read SEC document |
| May 16, 2017 Filed May 18, 2017 21:01 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 2,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-028455 · v467410_4.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,715 F1 · shares: Represents an award of 2,565 Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · balance_after: Includes 2,500 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest over a three-year period beginning on October 10, 2017, 1,650 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018 and 2,565 shares of unvested Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018. Read SEC document |
| January 09, 2017 Filed Jan 31, 2017 23:49 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantOptions to Purchase Common Stock · Derivative | 2,750 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001144204-17-005180 · v457998_4.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2027-01-09 Read SEC document |
| January 09, 2017 Filed Jan 31, 2017 23:49 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-005180 · v457998_4.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,150 F1 · shares: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018. F2 · balance_after: Includes 4,150 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 13:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option · Derivative | 4,150 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001144204-16-127776 · v450347_4.xml · derivative · entry 2 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,150 Underlying: Common Stock · 4,150 shares Expires 2026-10-10 F1 · price: This grant was made in connection with the Reporting Person's appointment to the Issuer's board of directors, audit committee and nominating and corporate governance committee. F3 · derivative.exercise_date: The stock options vest in equal annual installments over a three-year period, commencing on the first anniversary of the grant date. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 13:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-16-127776 · v450347_4.xml · nonDerivative · entry 1 BROWN GREGORY B · CIK 0001373585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: This grant was made in connection with the Reporting Person's appointment to the Issuer's board of directors, audit committee and nominating and corporate governance committee. F2 · balance_after: Represents 2,500 shares of restricted stock that will vest in equal annual installments over a three-year period, commencing on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.